Elk Creek Partners’s Pacira BioSciences PCRX Stock Holding History

Elk Creek Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	$8.89M	Sell	265,146 -6,036	-2%	-$251K	1.53%	16
2019 Q4	$12.3M	Sell	271,182 -186,455	-41%	-$7.92M	1.41%	16
2019 Q3	$17.4M	Sell	457,637 -42,432	-8%	-$1.69M	1.5%	12
2019 Q2	$21.7M	Sell	500,069 -64,507	-11%	-$2.74M	1.63%	6
2019 Q1	$21.5M	Buy	564,576 +28,382	+5%	+$1.11M	1.55%	12
2018 Q4	$23.1M	Sell	536,194 -189,201	-26%	-$8.83M	1.91%	7
2018 Q3	$35.7M	Sell	725,395 -643,665	-47%	-$27.8M	1.92%	6
2018 Q2	$43.9M	Buy	1,369,060 +366,749	+37%	+$12.7M	2.41%	2
2018 Q1	$31.2M	Buy	1,002,311 +341,520	+52%	+$12.2M	1.82%	8
2017 Q4	$30.2M	Buy	660,791 +48,742	+8%	+$1.93M	1.77%	7
2017 Q3	$23M	Buy	612,049 +59,393	+11%	+$2.39M	1.45%	12
2017 Q2	$26.4M	Buy	552,656 +540	+0.1%	+$25.1K	1.71%	8
2017 Q1	$25.2M	Buy	552,116 +104,259	+23%	+$4.51M	1.54%	13
2016 Q4	$14.5M	Sell	447,857 -10,591	-2%	-$353K	0.98%	37
2016 Q3	$15.7M	Buy	458,448 +23,749	+5%	+$930K	1.03%	32
2016 Q2	$14.7M	Buy	434,699 +45,141	+12%	+$2.22M	1.04%	34
2016 Q1	$20.6M	Buy	389,558 +44,758	+13%	+$2.62M	1.53%	12
2015 Q4	$26.5M	Sell	344,800 -29,073	-8%	-$1.65M	1.88%	6
2015 Q3	$15.4M	Buy	373,873 +302,173	+421%	+$18.5M	1.24%	21
2015 Q2	$5.07M	Buy	+71,700	New	+$5.65M	0.46%	96

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Elk Creek Partners's PCRX Position: Q1 2020 in Review

Elk Creek Partners reduced its Pacira BioSciences (PCRX) stake by 2.2% in Q1 2020, selling an estimated $251K and leaving 265,146 shares worth $8.89M. The position accounts for 1.53% of the portfolio, ranked #16.

Elk Creek Partners first reported a position in PCRX in Q2 2015 and has held it in 20 quarters since. The position peaked at $43.9M in Q2 2018. 226 funds tracked by Wall St. Rank hold PCRX as of Q1 2020.

Elk Creek Partners held 265,146 shares of Pacira BioSciences worth $8.89M as of Q1 2020.
Elk Creek Partners sold 6,036 Pacira BioSciences shares in Q1 2020, an estimated $251K.
Pacira BioSciences made up 1.53% of Elk Creek Partners's portfolio in Q1 2020, its #16 holding.
Elk Creek Partners first reported a position in Pacira BioSciences in Q2 2015 and has held it in 20 quarters since.
Elk Creek Partners's Pacira BioSciences position peaked at $43.9M in Q2 2018.
226 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2020.

Based on Elk Creek Partners's 13F filing for Q1 2020, filed 14 May 2020.